Lyman GH - Search Results

1

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update.

Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Francis CW, Gates LE, Kakkar AK, Levine MN, Liebman HA, Tempero MA, Lyman GH, Falanga A. Key NS, et al. Among authors: lyman gh. J Clin Oncol. 2020 Feb 10;38(5):496-520. doi: 10.1200/JCO.19.01461. Epub 2019 Aug 5. J Clin Oncol. 2020. PMID: 31381464

2

Basic population and cancer genetics and their use in the assessment of cancer risk.

Lyman GH, Kuderer NM. Lyman GH, et al. Eur J Cancer. 1997 Nov;33(13):2160-6. doi: 10.1016/s0959-8049(97)00307-9. Eur J Cancer. 1997. PMID: 9470801 Review. No abstract available.

3

Economic impact of granulopoiesis stimulating agents on the management of febrile neutropenia.

Lyman GH, Kuderer NM, Balducci L. Lyman GH, et al. Curr Opin Oncol. 1998 Jul;10(4):291-6. doi: 10.1097/00001622-199807000-00003. Curr Opin Oncol. 1998. PMID: 9702395 Review.

4

The economics of febrile neutropenia: implications for the use of colony-stimulating factors.

Lyman GH, Kuderer N, Greene J, Balducci L. Lyman GH, et al. Eur J Cancer. 1998 Nov;34(12):1857-64. doi: 10.1016/s0959-8049(98)00222-6. Eur J Cancer. 1998. PMID: 10023306

5

Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis.

Lyman GH, Kuderer NM, Djulbegovic B. Lyman GH, et al. Am J Med. 2002 Apr 1;112(5):406-11. doi: 10.1016/s0002-9343(02)01036-7. Am J Med. 2002. PMID: 11904116

6

Cost-benefit analysis of granulocyte colony-stimulating factor in the management of elderly cancer patients.

Lyman GH, Kuderer NM, Balducci L. Lyman GH, et al. Curr Opin Hematol. 2002 May;9(3):207-14. doi: 10.1097/00062752-200205000-00006. Curr Opin Hematol. 2002. PMID: 11953666 Review.

7

Filgrastim in patients with neutropenia: potential effects on quality of life.

Lyman GH, Kuderer NM. Lyman GH, et al. Drugs. 2002;62 Suppl 1:65-78. doi: 10.2165/00003495-200262001-00005. Drugs. 2002. PMID: 12479595 Review.

8

Cost effectiveness of myeloid growth factors in cancer chemotherapy.

Lyman GH, Kuderer NM. Lyman GH, et al. Curr Hematol Rep. 2003 Nov;2(6):471-9. Curr Hematol Rep. 2003. PMID: 14561391 Review.

9

Evidence-based use of colony-stimulating factors in elderly cancer patients.

Lyman GH, Kuderer N, Agboola O, Balducci L. Lyman GH, et al. Cancer Control. 2003 Nov-Dec;10(6):487-99. doi: 10.1177/107327480301000607. Cancer Control. 2003. PMID: 14652525 Free article. Review.

10

The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia.

Lyman GH, Kuderer NM. Lyman GH, et al. Crit Rev Oncol Hematol. 2004 May;50(2):129-46. doi: 10.1016/j.critrevonc.2004.01.001. Crit Rev Oncol Hematol. 2004. PMID: 15157662 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

572 results

Search Page

Filters